BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention.

Sergio Stagnaro,Simone Caramel

doi:10.3389/fgene.2013.00039

Abstract

BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention.

Highlights

In the present article we suggest an original clinical tool for the diagnosis of Inherited Real Risk (IRR) of breast cancer which can support the current sophisticated ways for breast cancer risk assessment such as, e.g., the traditional breast physical examination, and the denaturing high performance liquid chromatography (DHPLC) to screen for mutations of BRCA1- BRCA-2 (Kadouri et al, 2007), which have been linked to hereditary breast and ovarian cancer, and inheriting this mutation increases the risk of developing breast/ovarian cancer
It is a scientific transdisciplinary approach that is based on the “Congenital Acidosic Enzyme-Metabolic Histangiopathy” (CAEMH) (Stagnaro and Caramel, 2010), a unique mitochondrial cytopathy that is present at birth and subject to medical therapy
The presence of intense CAEMH in a well-defined area is due to gene mutations in both n-DNA and mit-DNA. This is the basis for one or more Quantum Biophysical Semeiotics (QBS) constitutions (Stagnaro and StagnaroNeri, 2004b), in our case, Oncological Terrain (Stagnaro, 2004), which could bring about their respective IRR, i.e., IRR of cancer (Stagnaro, 2009; Stagnaro and Caramel, 2012, 2013a,b)

Summary

Introduction

As regards the interesting discovery of a novel BRCA1 mutation in a family of Palestinian Arabian origin (Kadouri et al, 2007), we would like to state that all gene mutations bring about necessarily local biological activity modification, otherwise, gene mutations would be meaningless innocent bystanders (Stagnaro-Neri and Stagnaro, 1995; Kadouri et al, 2007; Stagnaro, 2008). With the aid of QBS method, physicians can bedside recognize, in an easy, quick, and reliable manner, the possible presence of maternally-inherited Oncological Terrain, and Oncological terrain-dependent, IRR, based on the presence of typical microcirculatory remodeling of mamma microvessels, due to newborn-pathological, type I, subtype (a) Oncological, EBDs (Stagnaro and Stagnaro-Neri, 2004a; Stagnaro and Caramel, 2010), conditio sine qua non of breast cancer (Stagnaro, 2009).

Results

Conclusion